204 related articles for article (PubMed ID: 34748872)
21. Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhance inhibition in pancreatic cancer.
Chen H; Wang X; Liu M; Yang J; Kuang Y; Wei R; Tai Z; Zhu Q; Chen Z; Chen J; Wu X
Int J Pharm; 2023 Dec; 648():123623. PubMed ID: 37989402
[TBL] [Abstract][Full Text] [Related]
22. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
23. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
[TBL] [Abstract][Full Text] [Related]
25. Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer.
Wang Y; Chen L; Zhang Z; Liu W; Li L
Drug Deliv Transl Res; 2022 Oct; 12(10):2537-2549. PubMed ID: 35043372
[TBL] [Abstract][Full Text] [Related]
26. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
27. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
28. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.
Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H
Int J Pharm; 2016 May; 505(1-2):139-46. PubMed ID: 27012982
[TBL] [Abstract][Full Text] [Related]
30. A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting.
Liu Y; Li D; Guo X; Xu H; Li Z; Zhang Y; Song C; Fan R; Tang X; Zhang Z
Int J Nanomedicine; 2017; 12():2227-2242. PubMed ID: 28356739
[TBL] [Abstract][Full Text] [Related]
31. High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach.
Taneja D; Namdeo A; Mishra PR; Khopade AJ; Jain NK
Drug Dev Ind Pharm; 2000 Dec; 26(12):1315-9. PubMed ID: 11147134
[TBL] [Abstract][Full Text] [Related]
32. Design and preparation of pH-sensitive cytotoxic liposomal formulations containing antitumor colchicine analogues for target release.
Shchegravina ES; Tretiakova DS; Sitdikova AR; Usova SD; Boldyrev IA; Alekseeva AS; Svirshchevskaya EV; Vodovozova EL; Fedorov AY
J Liposome Res; 2024 Sep; 34(3):399-410. PubMed ID: 37867342
[TBL] [Abstract][Full Text] [Related]
33. Lipophilic prodrug conjugates allow facile and rapid synthesis of high-loading capacity liposomes without the need for post-assembly purification.
Mikhalin AA; Evdokimov NM; Frolova LV; Magedov IV; Kornienko A; Johnston R; Rogelj S; Tartis MS
J Liposome Res; 2015 Sep; 25(3):232-260. PubMed ID: 25534989
[TBL] [Abstract][Full Text] [Related]
34. Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer.
Shah VM; Nguyen DX; Al Fatease A; Patel P; Cote B; Woo Y; Gheewala R; Pham Y; Huynh MG; Gannett C; Rao DA; Alani AWG
J Control Release; 2018 Dec; 291():169-183. PubMed ID: 30339904
[TBL] [Abstract][Full Text] [Related]
35. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
Andresen TL; Jensen SS; Jørgensen K
Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
[TBL] [Abstract][Full Text] [Related]
36. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
37. Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.
Tokunaga Y; Iwasa T; Fujisaki J; Sawai S; Kagayama A
Chem Pharm Bull (Tokyo); 1988 Sep; 36(9):3557-64. PubMed ID: 3149214
[No Abstract] [Full Text] [Related]
38. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
Yang MM; Wilson WR; Wu Z
Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
40. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
